JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $710 to $695.
JP Morgan analyst Jessica Fye maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and lowers the price target from $710 to $695.
More on UTHR
Benzinga
United Therapeutics Announces First Clinical Xenotransplant In Its EXTEND Study Of UThymoKidney In Patients With ESRDThe EXTEND study is the first clinical trial to evaluate xenotransplantation of a porcine thymokidney in a patient with end-stage renal disease (ESRD)EXTEND is the second clinical trial in United…
